Melanie Senior’s article in Nature Portfolio on ‘Precision Financing’ highlights the rigour behind private biotech financing in 2023 where strong data and efficiency are essential. Two of our clients, Naveed Siddiqi of Novo Holdings and Antoine Papiernik from Sofinnova Partners were featured. Here are some key takeaways… Since the pandemic, the biotech industry has experienced […]
Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]
MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]
Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future […]
Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in […]
